All In Biotech

Drug Trial Radar · NCT03082755

Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: May 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Jul 1, 2017

Primary completion

Aug 31, 2022

Study completion Mar 31, 2023

Sponsor

Lead sponsor
University of Texas at AustinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Aging (NIA)
First posted
Mar 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation. The investigators propose a clinical trial to better elucidate whether a sleep disorder, restless legs syndrome, may be a mechanism for nighttime agitation, and if treatment with gabapentin enacarbil (Horizant®) reduces nighttime agitation, improves sleep, reduces restless legs syndrome behaviors, and reduces antipsychotic medications.

Conditions

  • Alzheimer Disease

Interventions

  • Gabapentin EnacarbilDrug

    1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.

  • Placebo Oral TabletDrug

    1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nighttime Agitation - Cohen Mansfield Agitation Inventory (CMAI) - Direct ObservationTime frame: Change from baseline at 2 and 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas at Austin

    Austin, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.